Base excision repair as a therapeutic target in colon cancer

Clinical Cancer Research

Volumn 8, Issue 9, 2002, Pages 2985-2991

  Liu, Lili ^a   Nakatsuru, Yoko ^a   Gerson, Stanton L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; ALKYLATING AGENT; METHOXYAMINE; PROTEIN P53; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; EXCISION REPAIR; GENE MUTATION; MAXIMUM TOLERATED DOSE; MISMATCH REPAIR; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE PAIR MISMATCH; BONE MARROW DISEASES; CHROMOSOME ABERRATIONS; COLONIC NEOPLASMS; DACARBAZINE; DEOXYGUANOSINE; DNA ADDUCTS; DNA REPAIR; DNA, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYLAMINES; MICE; MICE, NUDE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SISTER CHROMATID EXCHANGE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036716989     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nitrosoureas from chemist to physician: Classification and recent approaches to drug design
2. DNA repair: Enzymatic mechanisms and relevance to drug response
3. Novel chemotherapeutic agents for the treatment of brain cancer
4. Novel oral chemotherapy agents
5. 6-alkylguanine-DNA AGT
6. 6-Benzylguanine and its role in chemotherapy
7. 6-Benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair
8. 6-methylguanine and the cytotoxicity of methylating agents
9. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1, 3-bis(2-chloroethyl)nitrosourea
10. Mammalian base excision repair and DNA polymerase β
11. Base excision repair initiation revealed by crystal structures and binding kinetics of human uracil-DNA glycosylase with DNA
12. A new approach to the study of the base-excision repair pathway using methoxyamine
13. Processing itt vitro of an abasic site reacted with methoxyamine: A new assay for the detection of abasic sites formed in vivo
14. Protection against methylation-induced cytotoxicity by DNA polymerase β-dependent long patch base excision repair
15. Pharmacologic disruption of base excision repair sensitizes mismatch repair deficient and proficient colon cancer cells to methylating agents
16. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells
17. Highly sensitive apurinic/apyrimidinic site assay can detect spontaneous and chemically induced depurination under physiological conditions
18. A method for detecting abasic sites in living cells: Age-dependent changes in base excision repair
19. Apurinic sites as mutagenic intermediates
20. Down-regulation of apurinic/apyrimidinic endonuclease expression is associated with the induction of apoptosis in differentiating myeloid leukemia cells
21. Effects of uracil incorporation. DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I
22. Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II
23. Application of fluorescence in situ hybridisation to studying the relationship between cytotoxicity, chromosomal aberrations and changes in chromosome number after treatment with the topoisomerase II inhibitor, amsacrine
24. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress
25. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
26. 6-methylguanine-DNA methyltransferase expression in acquired resistance to methylating agents in human cells
27. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer